Description
Using our intelligently designed and intuitive dataset, you can quickly understand how PTC Therapeutics (PTCT) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.
Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.
For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.
Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.
Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:
1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.
2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.
3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).
4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.
5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).
6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).
7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).
Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].
Frequently Asked Questions
What is PTC Therapeutics (PTCT) lobbying for?
Summary of PTC Therapeutics Lobbying Data:
– Lobbying firms hired: The Mcmanus Group, Thorn Run Partners, Bgr Government Affairs, Taylor Strategies, Ptc Therapeutics, Inc.
– General issues they lobbied on: Taxation/Internal Revenue Code, Medical/Disease Research/Clinical Labs, Health Issues, Medicare/Medicaid, Budget/Appropriations
– Specific issues they lobbied on: Accelerated Approval Pathway; H. R. 5375- Inflation Reduction Act of 2022, Issues relating to the adoption of value-based payment arrangements; H.R. 7389 – MVP Act; H.R. 2050- Huntingtons Disease Disability Insurance Access Act of 2021;, Drug approval through the FDA., Provide guidance and advocacy with regard to regulations and legislation that could impact the pharmaceutical industry generally, Issues related to the development of therapies for rare diseases. Federal Funding for Covid-19 therapies. Increased awareness for AADC deficiency. H. Res. 742, Issues related to the Orphan Drug Tax Credit; H.R. 1304 – American Innovation and R&D Competitiveness Act of 2021, as “AADC Deficiency Awareness Day”., Access and coverage of pharmaceuticals in Medicaid program and provisions included in Title I-Subtitle B of P.L. 117-169/H.R. 5376-Inflation Reduction Act of 2022. Education and awareness of rare and ultra rare diseases and patient access to orphan drugs., and PTC Therapeutics specifically., 2023., Issues related to FDA and drug development, 2021, Huntington’s Disease Parity Act, issues related to prescription drugs; H.R. 7667 and S.4348 – Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA Act), issues related to Prescription Drug User Fee Act (PDUFA), as “AADC Deficiency Awareness Day”. H.R.2050/S.868 – Huntingtons Disease Disability Insurance Access Act of 2021., H. Res. 742- AADC Deficiency Awareness Day, Designation of AADC Deficiency Awareness Day. S. 868/H.R. 2050, Issues related to the development of therapies for rare diseases. Federal Funding for Covid-19 therapies. Increased awareness for AADC deficiency. H.Res.742 – Supporting the designation of October 23, issues related to prescription drugs, as “AADC Deficiency Awareness Day”. H.R.2050/S.868 – Huntingtons Disease Disability Insurance Access Act of 2021. H.R.2617 – Consolidated Appropriations Act, Education and awareness of rare and ultra rare diseases and patient access to
– Government agencies they lobbied: Natl Institutes of Health (NIH), House of Representatives, Department of Health & Human Services (HHS), Senate, Centers For Medicare and Medicaid Services (CMS)
One could infer that PTC Therapeutics is lobbying on these issues in order to influence government policies and regulations that will benefit their business, specifically in the area of drug development for rare diseases. This is because they have lobbied on issues related to FDA drug approval, increased funding for Covid-19 therapies, and the adoption of value-based payment arrangements. Additionally, the company has lobbied on specific bills related to Huntington’s disease and AADC deficiency, which are both rare diseases that PTC Therapeutics focuses on treating. Furthermore, they have lobbied government agencies such as the National Institutes of Health and the Department of Health & Human Services, suggesting that they are seeking to advocate for policies that will improve patient access to their treatments and increase awareness of rare diseases.
